Better Growth Biotech Buy: Iovance Biotherapeutics vs CRISPR Therapeutics [Yahoo! Finance]
Iovance Biotherapeutics, Inc. (IOVA)
Last iovance biotherapeutics, inc. earnings: 2/25 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
iovance.com
Company Research
Source: Yahoo! Finance
Such a treatment will represent a brand new revenue driver for the company -- and sometimes, even its first one -- so if the product takes off, the share price may follow. In many cases, this marks the very start of the biotech's growth story, allowing you to get in early and benefit over time. This is the case for Iovance Biotherapeutics (NASDAQ: IOVA) and CRISPR Therapeutics (NASDAQ: CRSP) today. Each of these biotech players recently won approval for its first product -- and these aren't only regulatory victories, but also votes of confidence in the game-changing technologies they have developed. These stocks both represent interesting growth opportunities today. But if you could only choose one to add to your portfolio, which would be the better buy? The case for Iovance Iovance recently won accelerated approval for Amtagvi, generically known as lifileucel, a treatment for advanced melanoma -- the most dangerous form of skin cancer. The biotech company has developed an excit
Show less
Read more
Impact Snapshot
Event Time:
IOVA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
IOVA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
IOVA alerts
High impacting Iovance Biotherapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
IOVA
News
- With 63% ownership of the shares, Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) is heavily dominated by institutional owners [Yahoo! Finance]Yahoo! Finance
- Where Will Iovance Biotherapeutics Stock Be in 5 Years? [Yahoo! Finance]Yahoo! Finance
- 3 Millionaire-Maker Biotech Stocks [Yahoo! Finance]Yahoo! Finance
- Iovance Biotherapeutics to Present Clinical and Translational Data at 2024 ASCO Annual MeetingGlobeNewswire
- These Biotech Stocks Could Soar 120% and 295%, According to Wall Street [Yahoo! Finance]Yahoo! Finance
IOVA
Earnings
- 2/28/24 - Miss
IOVA
Sec Filings
- 4/17/24 - Form 4
- 4/17/24 - Form 4
- 4/17/24 - Form 4
- IOVA's page on the SEC website